RGNX Read Through: RGX-202 Pivotal Data Bodes Well For SLDB's SGT-003 in DMD

Research evidence excerpt

RGNX Read Through: RGX-202 Pivotal Data Bodes Well For SLDB's SGT-003 in DMD

Quick Note

May 14, 2026 Solid Biosciences Inc. (SLDB)

Rating: RGNX Read Through: RGX-202 Pivotal Data Bodes Well ForOUTPERFORM SLDB's SGT-003 in DMDPrice:

$7.38

12-Month Price Target: The Wedbush View: Remain Outperform rated on SLDB. RGNX (not covered)

$16.00 reported top-line Phase 3 AFFINITY DUCHENNE data for RGX-202. While overall

microdystrophin expression appeared robust (71% via Western Blot at week 12),

RGNX also reported 2 SAEs (subacute myocarditis, liver injury). We see positive

Analysts read through to SLDB. We view SGT-003 holding an easier immune suppression

Laura Chico, Ph.D. regimen with preliminary microdystrophin data that looks at least on par. Pairing(212) 668-9868

Laura.Chico@wedbush.com this with the IMPACT study already underway, and SLDB remains on "solid footing"

Thomas Yip with SGT-003.

(707) 521-2281

thomas.yip@wedbush.com RGNX rolls out pivotal RGX-202 results. The Phase 3 portion of the AFFINITY

DUCHENNE study evaluated 2e14 gc/kg RGX-202 (RGNX, not covered) in ~30

ambulatory DMD patients aged 1yr and older. The primary endpoint of the study

evaluated the proportion of patients with microdystrophin expression at/above

10% at week 12.

● Efficacy. Mean RGX-202 microdystrophin expression (via Western Blot) reached

71% overall at week 12. Higher expression shown in younger (<4yrs) patients

with 4-7yrs cohort achieving 58% (n=9). SRPT's (Outperform, Zhong) Elevidys

generated an average 34% expression in the same age group.

● Safety. Two SAEs were reported (subacute myocarditis, liver injury) with both

fully resolving. RGNX incorporated an immune suppression regimen including

eculizumab (5 doses), and overlapping sirolimus and steroids.